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Abstract
Introduction: The relationship between Hashimoto’s thyroiditis (HT) and thyroid cancer (TC) is controversial. While most surgical studies 
report a high incidence of malignancy among patients with HT, cytological studies do not. The role of autoantibodies in the incidence of 
malignancy is unclear. 
Material and methods: A single-centre retrospective observational study was conducted in patients evaluated for thyroid nodules by 
US-guided fine-needle aspiration cytology (FNAC) and, if indicated, by surgery. The levels of thyroid-stimulating hormone (TSH) and 
anti-thyroid antibodies were measured at the time of FNAC. 
Results: Of 4947 patients, 599 (12.1%) were diagnosed with HT. A malignant/suspicious cytological result was found in 14.2% of the pa-
tients with HT and in 15.2% of the others. The odds ratio (OR) for malignancy in HT was 0.921 (0.716–1.183, p = 0.51). Of 1603 patients 
who underwent surgery, differentiated thyroid carcinoma was found in 29.5% of the HT patients and in 15.2% of the others (OR 2.33, 
95% confidence interval CI, 1.403–3.854, p < 0,001). Low TSH (< 0.4 mIU/L) decreased the malignancy rate in the entire patient popula-
tion, both when considering the cytological results and the surgical results. This was not confirmed in the subgroup diagnosed with HT. 
No relationship was observed between autoantibodies against thyroid peroxidase (ATP) or thyroglobulin (ATG) and malignancy rate. 
Conclusions: No association between HT and thyroid cancer was observed cytologically; a positive relationship in histological series was 
caused by selection bias. Low TSH levels decreased the risk of TC in patients with nodular goitre, but this has not been proven in patients 
with HT. (Endokrynol Pol 2016; 67 (1): 48–53)
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Streszczenie
Wstęp: Związek pomiędzy zapaleniem tarczycy Hashimoto (HT) i rakiem tarczycy (TC) jest uważany za kontrowersyjny. Podczas gdy 
większość badań nad operacjami dokumentuje wysoką częstotliwość występowania guzów wśród pacjentów z HT, badania cytologiczne 
tego nie potwierdzają. Rola autoprzeciwciał w częstotliwości występowania guzów nie jest do końca jasna.
Materiał i metody: Wśród pacjentów, u których stwierdzono guzki tarczycy przeprowadzono jednoośrodkowe, retrospektywne badanie 
obserwacyjne poprzez aspiracyjną cytologię cienkoigłową (FNAC) pod kontrolą USG oraz operacyjnie, jeśli takie było wskazanie. Stężenia 
tyreotropiny (TSH) oraz przeciwciał przeciwtarczycowych zmierzono podczas przeprowadzania FNAC.
Wyniki: Z 4947 pacjentów, u 599 (12,1%) zdiagnozowano HT. Zły/podejrzany wynik cytologii stwierdzono u 14,2% pacjentów z HT oraz 
u 15,2% innych pacjentów. Iloraz szans (OR) dla guza przy HT wynosił 0,921 (0,716–1,183, p = 0,51). Z 1603 pacjentów, których poddano 
operacji, zróżnicowanego raka tarczycy wykryto u 29,5% pacjentów z HT i u 15,2% innych pacjentów (OR 2,33; 95% CI; 1,403–3,854, 
p < 0,001). Niski poziom TSH (< 0,4 mIU/l) obniża wskaźnik występowania guza w całej populacji pacjentów, zarówno gdy bierze się 
pod uwagę wyniki cytologiczne, jak i operacyjne. Nie zostało to potwierdzone w podgrupie, u której zdiagnozowano HT. Nie zaob-
serwowano związku pomiędzy autoprzeciwciałami przeciw peroksydazie tarczycowej (ATP) lub tyreoglobulinie (ATG) i wskaźnikiem 
występowania guzów.
Wnioski: Nie zaobserwowano cytologicznego związku pomiędzy HT i rakiem tarczycy; dodatni związek w seriach histologicznych 
spowodowany był stronniczością selekcji. Niskie stężenie TSH obniżył ryzyko TC u pacjentów z wolem guzkowym, lecz nie zostało to 
udowodnione u pacjentów z HT. (Endokrynol Pol 2016; 67 (1): 48–53)
Słowa kluczowe: rak tarczycy; guzek tarczycy; biopsja, biopsja cienkoigłowa, zapalenie tarczycy
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analysed retrospectively. The study was approved by 
the Local Ethics Committee. All FNACs were performed 
under ultrasound (US) guidance. Results were clas-
sified as unsatisfactory (non-diagnostic), benign, or 
malignant/suspicious (undetermined). Unsatisfactory 
aspirates were excluded from further analysis. The 
results were classified as unsatisfactory if there were 
fewer than ten groups of cells, each containing at least 
ten elements. Nodular goitre with or without regressive 
changes, granulomatous (de Quervain’s) thyroiditis, 
and chronic lymphocytic inflammation of variable 
intensity interpreted as either focal lymphocytic thy-
roiditis or HT were included as benign. The ‘malignant/ 
/suspicious’ category included follicular neoplasia, 
papillary carcinoma, anaplastic carcinoma, medul-
lary carcinoma, lymphoma, and metastatic tumours. 
These cases were diagnosed either as unequivocally 
malignant or with varying degrees of certainty. Cases 
with uncertain cytological findings that could not rule 
out malignancy were also included in the malignant 
category. The histopathological examination was 
performed after surgery (hemithyroidectomy or total 
thyroidectomy). The histological results were classified 
as benign (nodular goitre, follicular adenoma, or HT) 
or malignant (follicular carcinoma, papillary carcinoma, 
anaplastic carcinoma, medullary carcinoma, lymphoma, 
or metastatic neoplasms). Anaplastic, medullary and 
metastatic tumours together with lymphoma were 
excluded from final analysis. Since it is virtually impos-
sible to identify papillary microcarcinomas by aspiration 
cytology (these neoplasms were found only by chance 
in patients operated for suspicious FNAC from another 
nodule), and since these tumours have a negligible ma-
lignant potential, incidentally histologically identified 
microcarcinomas were also included as benign lesions. 
Altogether 823 patients underwent FNAC several 
times. A patient was considered positive when at least 
one of the cytological results was classified as suspi-
cious/malignant. The result was repeatedly non-diag-
nostic in 305 cases. After exclusion of 17 lymphomas, 
18 medullary, 13 anaplastic, and 14 metastatic tumours, 
4947 patients left for evaluation (Fig. 1). 
A comparison of our classification to Bethesda 
classification, including sensitivity and specificity, was 
published previously [12]. A total of 1660 patients from 
4947 patients with FNAC underwent thyroidectomy. 
We excluded histological diagnoses of 11 lymphomas, 
18 medullary, 13 anaplastic ,and 14 metastatic carcino-
mas, so that 1603 histological results remained for evalu-
ation. HT was recognised clinically if at least two of three 
criteria (thyroid antibodies, typical sonographic finding, 
and/or TSH above normal ranges) were satisfied. 
The levels of TSH and anti-thyroid antibodies were 
detected at the time of FNAC using commercial assays. 
Introduction
Among endocrine tumours, thyroid cancer (TC) is the most 
common malignancy. According to the National Oncologi-
cal Registry of the Czech Republic, the 2011 incidence of 
malignant thyroid neoplasms was 6.6/100,000 individuals 
[1]. Papillary thyroid cancer (PTC) is the most frequent TC, 
representing 70–80% of all TCs. Hashimoto’s thyroiditis 
(HT) is the most common autoimmune thyroid disease, 
with an incidence of 30–150 per 100,000 individuals world-
wide and striking predominance in females (5–20:1). The 
relationship between HT and TC has not yet been fully 
ascertained. According to recent review [2], a significant dif-
ference was observed between population-based studies of 
fine-needle aspiration cytology (FNAC) and thyroidectomy 
studies. In population-based studies of FNAC from thyroid 
nodules, no positive correlation was detected between HT 
and PTC, and the prevalence of PTC in patients with HT 
was 1.2% with an average risk ratio of 0.69. By contrast, in 
studies evaluating histology after thyroidectomy, a posi-
tive relationship was reported: the prevalence of PTC in 
patients with HT was 27.56% with an average risk ratio 
of 1.59 [2]. Unfortunately, the studies evaluated in that 
review were vulnerable to bias. In a group of patients 
with HT, the risk of developing TC was 1.68-fold higher 
than in a control cohort of non-HT patients [3]. In another 
study, the incidence of PTC was higher only in patients 
with a nodular form of HT compared to patients with 
nodular goitre without HT [4]. HT was present in 23.2% 
of patients with PTC in a recent meta-analysis and was 
associated with favourable clinicopathological features [5]. 
Thyroid-stimulating hormone (TSH) levels, starting with 
the normal range, were positively associated with PTC in 
patients with HT, who underwent thyroidectomy [6, 7]; 
however, in another study, the TSH concentration was not 
different between patients with PTC or benign disease [8]. 
Thus, the relationship between anti-thyroid antibodies and 
the incidence of thyroid carcinoma (TC) remains contro-
versial. In several studies, positivity for thyroid peroxidase 
antibody did not correlate with the malignancy rate [1, 4] 
while in other studies it showed inverse correlation with 
malignancy rate [9]. By contrast, anti-thyroglobulin (ATG) 
antibody positivity was associated with a slightly increased 
relative risk of thyroid carcinoma [1, 3, 10, 11]. 
The present retrospective study of human clinical 
specimens investigated FNAC and pathology results to 
evaluate their association with HT, serum TSH levels, 
and anti-thyroid antibody positivity.  
Material and methods
The results of 6411 FNAC of thyroid nodules performed 
in 5333 adult patients (14.1% men and 85.9% women) 
between 1991 and 2014 in the Endocrinology Unit were 
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Statistics
The odds ratio (OR) for the existence of TC in the pres-
ence of HT, ATG, and anti-thyroid peroxidase (ATP) 
antibody positivity and low TSH (< 0.4 mIU/L) were 
calculated. The 95% confidence intervals (CI) were 
determined using online biostatistical software (http://
statpages.org/ctab2x2.html). Fisher’s exact test and Chi 
square test were used, and a two-tailed p value ≤ 0.05 
was considered statistically significant.
Results
Cytological studies
FNAC results were evaluated in 4947 patients. At the 
time of FNAC, 599 (12.1%) patients with clinically 
diagnosed HT (HTpos) had nodules identified by US. 
Of these, benign results included nodular goitre in 
98 (16.4%), HT in 413 (68.9%), and de Quervain’s 
thyroiditis in 3 (0.5%) patients. Malignant/suspicious 
cytology was observed in 85 of 599 (14.2%) HT patients. 
In patients without clinical diagnosis of HT (HTneg), 
benign results included colloid nodules in 3614 (83.1%), 
HT in 8 (0.2%), granulomatous thyroiditis in 64 (1.7%), 
and other results (parathyroid gland lesion, lymph 
node) in 19 (0.4%) patients; the latter cases were ex-
cluded from further analysis. Malignant/suspicious 
FNAC results were present in 662 of 4348 cases (15.2%). 
The risk of suspicious cytology was not different be-
tween HTpos and HTneg patients (OR 0.92, p = 0.51). 
Data are shown in Table I and II.
Surgical studies
Altogether, histological results of 1603 patients were 
evaluated. Malignancy was found in 26 of 88 HTpos 
and in 231 of 1515 HTneg patients. The malignancy rate 
was 29.5% and 15.2%, respectively. In histological series, 
the rate of differentiated thyroid carcinoma was higher 
in HTpos patients than in HTneg patients (OR 2.33). 
This difference was statistically significant (p < 0.001) 
TSH levels
The level of TSH measured at the time of FNAC was 
available in 2268 patients. The malignancy rate was 
calculated based on the TSH level, which was either 
low (< 0.4 mIU/L) or higher (≥ 0.4 mIU/L) (Table III). 
Low TSH was associated with a low probability of dif-
Figure 1. Study profile
Rycina 1. Profil badania
5333
patients
305 repeatedly
unsatisfactory FNAC
62 FNAC anaplastic, medullary,
metastatic carcinoma or lymphoma
19 parathyroid adenoma,
lymph node
4947 patients FNAC
evaluated
1660 operated on
57 anaplastic, medullary, metastatic
carcinoma or lymphoma histology
1603 histologically
evaluated
Table I. Results of FNAC according to clinical diagnosis. 
Cases with non-diagnostic FNAC (35 with Hashimoto´s 
thyroiditis and 270 without), anaplastic, medullary, 
metastatic carcinomas, and lymphomas were excluded
Tabela I. Wyniki FNAC według diagnozy kliniczej. Przypadki 
z FNAC nie do zdiagnozowania (35 z HT i 270 bez), raka 
anaplastycznego, raka rdzeniastego i raka z przerzutami oraz 
chłoniaki zostały wyłączone z badania
Cytological 
result
Clinical diagnosis Altogether
Hashimoto’s 
thyroiditis
Other
Thyroiditis 416 (69.5%) 72 (1.6%) 488 (9.9%)
Colloid nodule 98 (16.4%) 3.614 (83.1%) 3.712 (75.0%)
Suspicious 67 (11.2%) 499 (11.5%) 566 (11.4%)
Malignant 18 (3.0%) 163 (3.8%) 181 (3.7%)
Altogether 599 4.348 4.947
Table II. OR in this Table evaluates the ratio of malignancy in 
the presence (HTpos) or absence (HTneg) of clinical diagnosis 
of Hashimoto’s thyroiditis in cytological and histological 
series
Tabela II. Niniejszy OR ocenia wskaźnik występowania 
guzów w obecności (HTpozytywne) lub nieobecności 
(HTnegatywne) diagnozy klinicznej zapalenia tarczycy 
Hashimoto w seriach cytologicznych i histologicznych
FNA series Histology series
HTPOS HTNEG HTPOS HTNEG
Benign (n) 514 3686 62 1284
Malignant/susp. (n) 85 662 26 231
Malignancy rate (%) 14.2 15.2 29.5 15.2
OR 0.921 2.331
95% CI 0.716–1.183 1.403–3.854
Chi square test 0.507 < 0.001
Fisher’s exact test 0.543 0.001
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ferentiated thyroid carcinoma both cytologically (OR, 
0.719, p = 0.027) and histologically in surgical specimens 
(OR 0.503, p = 0.009). 
For HTpos patients the OR for malignancy in case of 
low TSH was 0.8, both in the cytological and histologi-
cal studies, and the difference did not reach statistical 
significance (p = 0.704 and p = 0.835, respectively). 
Interpretation is difficult since the number of such cases 
was low. For HTneg patients, the malignancy rate was 
lower in case of low TSH 10.9% vs. 22.6% (OR 0.417, 
95% CI 0.237–0.727, p = 0.001) in histological series and 
9.6 vs. 16.7 (OR 0.529, 95% CI 0.386–0.722, p < 0.001) in 
cytological series. 
Antibody positivity
The association of the FNAC results and surgical speci-
men histology with the presence of ATP and ATG au-
toantibodies is summarised in Table IV. The malignancy 
rate showed no correlation with the autoimmune status. 
Discussion
The relationship between HT and thyroid carcinoma 
was proposed for the first time by Dailey in 1955 [13]. 
His work was based on surgical pathology data; how-
ever, in 1985, Holm et al. [14] published results from 
a 22-year study of patients with HT, in which only 
2 of 829 patients developed TC. Many subsequent stud-
ies were published with controversial results. Among 
surgical studies, some demonstrated an association 
between HT [15–20] and TC, whereas others did not 
[21, 22]. In a systematic review published by Jankovic 
et al. [2], surgical studies showed a high incidence of 
PTC in HT. The average rate in eight retrospective thy-
roidectomy studies was 27.56%.
Recently, in a large series of 8524 patients who un-
derwent surgery, Zhang also observed a significantly 
higher incidence of PTC in HTpos (29.4%) than in 
HTneg (19.4%) patients [23]. We also found a signifi-
cantly higher incidence of TC in HTpos patients in our 
histological data. The prevalence was 29.5% for all 
differentiated TC. By contrast, several surgical studies 
reported that thyroid nodules are not more likely to be 
malignant in patients with HT than in patients without 
HT [22, 24]. Unfortunately, since the decision for sur-
gery is mostly based on suspicious cytology results, any 
demonstration of association between HT and PTC in 
surgical studies is strongly affected by a serious selec-
tion bias [2, 25]. The retrospective character of studies 
is another disadvantage. Differences in results between 
Table III. OR in this Table evaluates the ratio of malignancy in 
patients with TSH < 0.4 as compared to the group of patients 
TSH > 0.4 in 2268 patients in whom TSH level was measured 
at the time of FNAC
Tabela III. Niniejszy OR ocenia wskaźnik występowania 
guzów wśród pacjentów ze stężeniem TSH < 0,4 
w porównaniu z grupą pacjentów ze stężeniem TSH > 0,4 
w grupie 2268 pacjentów, u których stężenie TSH badano 
w czasie przeprowadzania FNAC
FNAC series Histology series
TSH  
< 0.4
TSH  
≥ 0.4
TSH  
< 0.4
TSH  
≥ 0.4
Benign (n) 608 1385 173 294
Malignant/susp. (n) 66 209 21 71
Malignancy rate (%) 9.8 13.1 10.8 19.5
OR 0.719 0.503
95% CI 0.531–0.973 0.288–0.871
Chi square test 0.027 0.009
Fisher’s exact test 0.029 0.008
Table IV. OR in this Table evaluates the ratio of malignancy according to the positivity of ATP (> 50 mIU/L) and ATG 
(> 300 mIU/L) in FNAC and histology series
Tabela IV. Niniejszy OR ocenia wskaźnik występowania guzów według podwyższonych stężeń ATP (> 50 mIU/l) i ATG 
(> 300 mIU/l) we FNAC i seriach histologicznych
FNAC series Histology series
ATP+ ATP– ATG+ ATG– ATP+ ATP– ATG+ ATG–
Benign (n) 513 1096 269 1340 85 300 44 346
Malignant/susp. (n) 84 197 44 225 17 66 8 75
Malignancy rate (%) 14.2 14.4 14.1 14.4 16.7 18.0 15.4 17.8
OR 0.987 0.978 0.888 0.839
95% CI 0.74–1.32 0.74–1.32 0.47–1.65 0.35–1.95
Chi square test 0.926 0.926 0.691 0.664
Fisher’s exact test 0.944 0.944 0.772 0.847
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individual studies may be caused, at least in part, by 
differences in the histopathological evaluation of the 
extent of lymphocytic infiltration in the tissue [24]. 
Controversial results were also reported in pop-
ulation-based studies of thyroid nodules by FNAC. 
Some studies reported an association between HT and 
TC [4, 6, 8], whereas others did not [25–31]. Possible 
sources of bias in Boi’s [6] and Fiore’s [4, 28] studies 
were discussed previously [25]. In a systematic review 
of cytological studies, [2] no positive correlation was 
observed between HT and PTC, and the prevalence 
of PTC in patients with HT was 1.2% with an average 
risk ratio of 0.69 [2]. Similar results were published re-
cently in a large cytological series of 2504 consecutive 
patients, in which the prevalence of results suggestive 
or indicative of malignancy was not different between 
the groups studied [25]. Similarly to Castagna et al., 
[25] we analysed cytology and surgical specimen his-
tology results in the same group of patients. Sample 
size is one of the strengths of our study. Our analysis 
of FNAC in 5314 patients showed no difference in risk 
of TC between patients with HT and patients without 
HT. Incidental microcarcinomas (less than 10 mm) were 
considered benign in histological series. There were 
7 microcarcinomas with clinical diagnosis of Hashimoto 
thyroiditis and 33 in other diagnoses. We recalculated 
statistics considering them as malignant histology and 
the result did not change considerably. 
High levels of TSH are associated with increased risk 
of TC [8, 10, 25, 28, 32, 33]. This was well-demonstrated 
in a review by McLeod et al.; [34] however, studies 
evaluating thyroid autoimmunity reported a lower OR 
for TC than other studies. In our study, we divided the 
population according to TSH level using a threshold 
of 0.4 mIU/L. In contrast to previous studies, we did 
not find any statistically significant difference in the 
incidence of malignant/suspicious FNAC result or 
histologically proven carcinoma between HT patients 
with normal TSH and HT patients with low TSH. This 
finding was published previously, [1] but in our series 
the number of histologically verified patients with HT 
was small. Among patients with nodular goitre, but not 
among patients with HT, the malignancy rate of TC was 
lower in patients with low TSH than in patients with 
normal TSH.
The relationship between thyroid autoantibodies 
and malignancy is controversial. Boelaert et al. [10] did 
not find any relationship between ATP antibody positiv-
ity and cancer risk after correction for TSH level. These 
results were also confirmed by others [4]. By contrast, 
in the study by Boi et al., positivity for autoantibodies 
(the authors did not specify whether thyroglobulin or 
thyroid peroxidase was assessed) was associated with 
increased probability of Bethesda IV category FNAC in 
patients under 53 years of age (OR, 2.29). Wong et al. 
[35] found that in patients with a previous benign FNAC 
result, malignant neoplasms confirmed by histology 
were more frequent in the presence than in the ab-
sence of thyroid antibodies (OR, 2.16). Similarly, in the 
study by Paparodis et al., [9] in patients with HT who 
were either euthyroid or treated with a high thyroxine 
dose, high ATP levels were significantly associated with 
a decreased incidence of TC. 
As to ATG autoantibody levels, Kim et al. [8] first 
reported an association between ATG positivity and 
TC (OR, 1.61), and this finding was confirmed by 
subsequent studies; however, a lack of association 
was reported too.[35] In our series, we were not able 
to demonstrate any association between ATG or ATP 
antibody levels and cancer risk. 
In conclusion, we confirmed, in a large patient 
population, no association between HT and TC based 
on cytology results. We also confirmed the fact that 
studies based on surgical specimens are strongly af-
fected by selection bias. Low TSH levels are associated 
with a decreased risk of TC in patients with nodular 
goitre without HT; however, this could not be proven in 
patients with HT in this series. In addition, the ATG and 
ATP autoantibody status had no impact on cancer risk. 
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